Jay S. Duker's most recent trade in EyePoint Pharmaceuticals Inc was a trade of 16,667 Common Stock done . Disclosure was reported to the exchange on July 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 16,667 | 17,653 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 16,667 | 16,667 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.06 per share. | 10 Jul 2025 | 7,688 | 9,965 (0%) | 0% | 11.1 | 85,029 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 8.21 per share. | 23 Jun 2025 | 56,665 | 986 (0%) | 0% | 8.2 | 465,220 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 6.16 per share. | 19 Mar 2025 | 20,000 | 57,651 (0%) | 0% | 6.2 | 123,100 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 7,000 | 79,706 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 7,000 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.49 per share. | 09 Feb 2025 | 2,055 | 77,651 (0%) | 0% | 6.5 | 13,347 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 390,000 | 390,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 195,000 | 228,334 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 60,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 68,027 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 20,794 | 78,814 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 20,794 | 39,206 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 03 Jan 2025 | 10,007 | 58,020 (0%) | 0% | 8.3 | 82,658 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 03 Jan 2025 | 6,108 | 72,706 (0%) | 0% | 8.7 | 53,017 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 16,666 | 46,086 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 16,666 | 33,334 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.69 per share. | 10 Jul 2024 | 8,059 | 38,027 (0%) | 0% | 8.7 | 70,033 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Feb 2024 | 2,500 | 29,420 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay Duker S. | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Feb 2024 | 2,500 | 22,500 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Duker S. Jay | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Feb 2024 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay Duker S. | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Feb 2024 | 20,000 | 31,920 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Duker S. Jay | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 7,000 | 50,486 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay Duker S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 7,000 | 7,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Duker S. Jay | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | S. Jay Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 55,453 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Duker Jay S. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 2,075 | 53,378 (0%) | 0% | 28.8 | 59,760 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,458 | 51,920 (0%) | 0% | 28.8 | 41,990 | Common Stock |
| EyePoint Pharmaceuticals Inc | Duker S. Jay | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | S. Duker Jay | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 90,000 | 90,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | S. Duker Jay | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 20,793 | 41,587 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Duker Jay S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 20,793 | 50,014 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | S. Duker Jay | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 6,528 | 43,486 (0%) | 0% | 20.4 | 133,171 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 62,380 | 62,380 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 7,000 | 28,402 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 7,000 | 14,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 33,369 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 4,967 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 2,426 | 30,943 (0%) | 0% | 4.2 | 10,116 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,722 | 29,221 (0%) | 0% | 4.2 | 7,181 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 124,755 | 124,755 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 15,258 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 15,258 | 25,881 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 01 Nov 2022 | 4,479 | 21,402 (0%) | 0% | 5.4 | 24,276 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2022 | 65,300 | 65,300 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jay S. Duker | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 239,700 | 239,700 | - | - | Stock Option (Right to Buy) |